These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 574746)

  • 1. Cyproheptadine effects on pituitary function.
    Dolman LI
    Ann Intern Med; 1979 Dec; 91(6):927. PubMed ID: 574746
    [No Abstract]   [Full Text] [Related]  

  • 2. Cyproheptadine in the management of the galactorrhea-amenorrhea syndrome.
    Wortsman J; Soler NG; Hirschowitz J
    Ann Intern Med; 1979 Jun; 90(6):923-5. PubMed ID: 571691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiserotonin treatment of hyperprolactinemic amenorrhea: long-term follow-up with metergoline, methysergide, and cyproheptadine.
    Crosignani PG; Peracchi M; Lombroso GC; Reschini E; Mattei A; Caccamo A; D'Alberton A
    Am J Obstet Gynecol; 1978 Oct; 132(3):307-12. PubMed ID: 707571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies on the effect of cyproheptadine on growth hormone secretion.
    Lamberts SW; MacLeod RM
    Proc Soc Exp Biol Med; 1979 Oct; 162(1):116-20. PubMed ID: 504217
    [No Abstract]   [Full Text] [Related]  

  • 5. [2-Br-alpha-ergocryptine in the treatment of amenorrhea-galactorrhea syndromes and in inhibition of puerperal lactation. Effect on secretion of prolactin and pituitary gonadotropin].
    Cagnazzo G; Schonauer S; Lodico G; Lotti G; Delitala G; Masala A
    Minerva Ginecol; 1976 Oct; 28(10):761-70. PubMed ID: 1036769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of cyproheptadine on chlorpromazine stimulation of prolactin in women.
    Board JA; Fierro RJ
    Am J Obstet Gynecol; 1981 Jan; 139(2):160-3. PubMed ID: 6109449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of stress-induced hyperprolactinaemia.
    Corenblum B; Whitaker M
    Br Med J; 1977 Nov; 2(6098):1328. PubMed ID: 201334
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of cyproheptadine on prolactin synthesis and release by normal and suppressed pituitary glands and by dispersed pituitary tumor cells.
    Lamberts SW; MacLeod RM
    Endocrinology; 1978 Nov; 103(5):1710-7. PubMed ID: 748012
    [No Abstract]   [Full Text] [Related]  

  • 9. Metergoline and cyproheptadine suppress prolactin release by a non-5-hydroxytryptaminergic, non-dopaminergic mechanism.
    Besser GM; Delitala G; Grossman A; Yeo T
    Br J Pharmacol; 1980 Sep; 70(1):5-7. PubMed ID: 7426830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bromocryptine therapy in cases of amenorrhea-galactorrhea.
    Mroueh AM; Siler-Khodr TM
    Am J Obstet Gynecol; 1977 Feb; 127(3):291-8. PubMed ID: 576372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ergolines as potential prolactin and mammary tumor inhibitors.
    Cassady JM; Floss HG
    Lloydia; 1977; 40(1):90-106. PubMed ID: 327183
    [No Abstract]   [Full Text] [Related]  

  • 12. Endocrine profile and therapeutic employment of a new prolactin-lowering drug, metergoline.
    Ferrari C; Reschini E; Peracchi M; Crosignani PG
    Gynecol Obstet Invest; 1980; 11(1):1-16. PubMed ID: 6248438
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapeutic use of bromocriptine in women with amenorrhea-galactorrhea and suspected pituitary microadenoma.
    Jewelewicz R
    Adv Biochem Psychopharmacol; 1980; 23():209-15. PubMed ID: 7395612
    [No Abstract]   [Full Text] [Related]  

  • 14. Prediction of response to ergocryptine in the galactorrhea-amenorrhea syndrome.
    Corenblum B; Taylor PJ
    Fertil Steril; 1978 Oct; 30(4):388-92. PubMed ID: 581377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of L-DOPA on serum prolactin in cases of galactorrhea-amenorrhea caused by a pituitary adenoma].
    Barreca T; Masturzo P; Rolandi E; Polleri A
    Boll Soc Ital Biol Sper; 1974 Nov; 50(21):1857-61. PubMed ID: 4477960
    [No Abstract]   [Full Text] [Related]  

  • 16. Inhibition of cyclic gonadotropin secretion by endogenous human prolactin.
    Tyson JE; Khojandi M; Huth J; Smith B; Thomas P
    Am J Obstet Gynecol; 1975 Feb; 121(3):375-9. PubMed ID: 1115151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [THE AMENORRHEA-GALACTORRHEA SYNDROME].
    PULLE C; RIGANO A
    Minerva Ginecol; 1964 Jan; 16():1-9. PubMed ID: 14124186
    [No Abstract]   [Full Text] [Related]  

  • 18. [Use of bromocriptine to induce ovulation in the galactorrhea-amenorrhea syndrome [].
    Hernández Ayup S; Muñoz M; González R; Galache P; Guitrón A; Pancardo RM; Forsbach G
    Rev Invest Clin; 1982; 34(2):121-3. PubMed ID: 7123023
    [No Abstract]   [Full Text] [Related]  

  • 19. Hyperprolactinemic primary amenorrhea: case report with successful prolactin-lowering treatment and review of the literature.
    Farrari C; Telloli P; Rampini P; Caldara R
    Gynecol Obstet Invest; 1980; 11(6):317-26. PubMed ID: 6785158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variation of serum prolactin-releasing activity in women with the galactorrhea-amenorrhea syndrome after bromocriptine treatment.
    Takahashi K; Minato K; Ikeno N; Watanabe M; Endo H; Yamamoto H
    Am J Obstet Gynecol; 1983 May; 146(1):74-9. PubMed ID: 6405619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.